Diagnostic Center | April 16, 2024
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Cipla completes transfer of Generics Business Undertaking
Subscribe To Our Newsletter & Stay Updated
